

Gene variant reduces cholesterol by two mechanisms

July 2 2012

High levels of low-density lipoprotein (LDL) cholesterol increases the risk for coronary heart disease.

A variant in the <u>human gene</u> encoding the protein sortilin is associated with reduced plasma LDL levels and a decreased risk of heart attack.

This variant results in markedly higher sortilin <u>protein expression</u> in liver.

Dr. Daniel Rader and colleagues at the University of Pennsylvania in Philadelphia have uncovered a two-pronged mechanism for the change in LDL observed.

Using a mouse model system, the Rader team found that increased liver sortilin is responsible for reducing secretion of APOB, a protein that transports LDL to tissue, and also triggers LDL breakdown.

Both of these effects were dependent on a cellular process known as lysosomal targeting.

Their data provide functional evidence that genetically-increased hepatic sortilin in humans reduces LDL by increasing LDL degradation, thus removing LDL from circulation, as well as decreasing APOB.

More information: Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism, *Journal of Clinical Investigation*.



Provided by Journal of Clinical Investigation

Citation: Gene variant reduces cholesterol by two mechanisms (2012, July 2) retrieved 6 May 2024 from <u>https://medicalxpress.com/news/2012-07-gene-variant-cholesterol-mechanisms.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.